Literature DB >> 11120976

Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.

D F Sahm1, I A Critchley, L J Kelly, J A Karlowsky, D C Mayfield, C Thornsberry, Y R Mauriz, J Kahn.   

Abstract

Given the propensity for Enterobacteriaceae and clinically significant nonfermentative gram-negative bacilli to acquire antimicrobial resistance, consistent surveillance of the activities of agents commonly prescribed to treat infections arising from these organisms is imperative. This study determined the activities of two fluoroquinolones, levofloxacin and ciprofloxacin, and seven comparative agents against recent clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia using two surveillance strategies: 1) centralized in vitro susceptibility testing of isolates collected from 27 hospital laboratories across the United States and 2) analysis of data from The Surveillance Network Database-USA, an electronic surveillance network comprising more than 200 laboratories nationwide. Regardless of the surveillance method, Enterobacteriaceae, P. aeruginosa, and A. baumannii demonstrated similar rates of susceptibility to levofloxacin and ciprofloxacin. Susceptibilities to the fluoroquinolones approached or exceeded 90% for all Enterobacteriaceae except Providencia spp. (</=65%). Approximately 70% of P. aeruginosa and 50% of A. baumanii isolates were susceptible to both fluoroquinolones. Among S. maltophilia isolates, 50% more isolates were susceptible to levofloxacin than to ciprofloxacin. Overall, the rate of ceftazidime nonsusceptibility among Enterobacteriaceae was 8.7%, with fluoroquinolone resistance rates notably higher among ceftazidime-nonsusceptible isolates than ceftazidime-susceptible ones. Multidrug-resistant isolates were present among all species tested but were most prevalent for Klebsiella pneumoniae and Enterobacter cloacae. No gram-negative isolates resistant only to a fluoroquinolone were encountered, regardless of species. Thus, while levofloxacin and ciprofloxacin have maintained potent activity against Enterobacteriaceae, the potential for fluoroquinolone resistance, the apparent association between fluoroquinolone and cephalosporin resistance, and the presence of multidrug resistance in every species examined emphasize the need to maintain active surveillance of resistance patterns among gram-negative bacilli.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120976      PMCID: PMC90271          DOI: 10.1128/AAC.45.1.267-274.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA.

Authors:  D F Sahm; M K Marsilio; G Piazza
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

2.  Susceptibility surveillance among gram-negative bacilli at a cancer center.

Authors:  K Jacobson; K Rolston; L Elting; B LeBlanc; E Whimbey; D H Ho
Journal:  Chemotherapy       Date:  1999 Sep-Oct       Impact factor: 2.544

Review 3.  Antibiotic resistance caused by gram-negative multidrug efflux pumps.

Authors:  H Nikaido
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079

Review 4.  Consequences of increasing resistance to antimicrobial agents.

Authors:  J F Acar; F W Goldstein
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079

Review 5.  Trends in bacterial resistance to fluoroquinolones.

Authors:  J F Acar; F W Goldstein
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

Review 6.  Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia.

Authors:  R N Jones
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

7.  Evidence of interhospital transmission of extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in the United States, 1986 to 1993. The National Nosocomial Infections Surveillance System.

Authors:  D L Monnet; J W Biddle; J R Edwards; D H Culver; J S Tolson; W J Martone; F C Tenover; R P Gaynes
Journal:  Infect Control Hosp Epidemiol       Date:  1997-07       Impact factor: 3.254

8.  Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.

Authors:  J Wiener; J P Quinn; P A Bradford; R V Goering; C Nathan; K Bush; R A Weinstein
Journal:  JAMA       Date:  1999-02-10       Impact factor: 56.272

9.  gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae.

Authors:  L M Weigel; C D Steward; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Bacterial resistance to ciprofloxacin in Greece: results from the National Electronic Surveillance System. Greek Network for the Surveillance of Antimicrobial Resistance.

Authors:  A C Vatopoulos; V Kalapothaki; N J Legakis
Journal:  Emerg Infect Dis       Date:  1999 May-Jun       Impact factor: 6.883

View more
  23 in total

1.  Biographical Feature: Clyde Thornsberry, Ph.D.

Authors:  Erik Munson
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

2.  [Soft tissue infections in oral, maxillofacial, and plastic surgery. Bacterial spectra and antibiotics].

Authors:  A W Eckert; P Maurer; D Wilhelms; J Schubert
Journal:  Mund Kiefer Gesichtschir       Date:  2005-11

3.  Posttreatment changes in Escherichia coli antimicrobial susceptibility rates among diarrheic patients treated with ciprofloxacin.

Authors:  Shannon D Putnam; John W Sanders; David R Tribble; David R Rockabrand; Mark S Riddle; Patrick J Rozmajzl; Robert W Frenck
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

4.  Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study.

Authors:  James A Karlowsky; Daryl J Hoban; Melanie R Decorby; Nancy M Laing; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.

Authors:  Mario Tumbarello; Teresa Spanu; Maurizio Sanguinetti; Rita Citton; Eva Montuori; Fiammetta Leone; Giovanni Fadda; Roberto Cauda
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

6.  Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility.

Authors:  Jennifer H Han; Warren B Bilker; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2013-08-23       Impact factor: 3.254

Review 7.  Integrated Multilevel Surveillance of the World's Infecting Microbes and Their Resistance to Antimicrobial Agents.

Authors:  Thomas F O'Brien; John Stelling
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

8.  Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001.

Authors:  James A Karlowsky; Deborah C Draghi; Mark E Jones; Clyde Thornsberry; Ian R Friedland; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

9.  Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States.

Authors:  James A Karlowsky; Laurie J Kelly; Clyde Thornsberry; Mark E Jones; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy.

Authors:  Richard P Wenzel; Daniel F Sahm; Clyde Thornsberry; Deborah C Draghi; Mark E Jones; James A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.